<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706390</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19vacc-1</org_study_id>
    <nct_id>NCT04706390</nct_id>
  </id_info>
  <brief_title>Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination</brief_title>
  <acronym>COVID19vac-1</acronym>
  <official_title>Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bergen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has been intensified by no&#xD;
      population-based immunity to the severe acute respiratory disease coronavirus 2 (SARS-CoV2)&#xD;
      and initially lack of effective treatments or vaccines available to mitigate the pandemic.&#xD;
      Currently, two COVID-19 vaccines are available for vaccination in Europe through conditional&#xD;
      marketing authorisation granted by the European Medicines Agency and further vaccine will be&#xD;
      licensed. These vaccines have shown good vaccine efficacy in phase 3 vaccine trials. We will&#xD;
      recruit subjects who will be prioritised for vaccination with the primary aim of comparing&#xD;
      the immune responses after COVID-19 vaccination and natural SARS-CoV-2 infection. In Western&#xD;
      Norway we have recruited cohorts of health care workers and patients infected with SARS-CoV-2&#xD;
      and will extend to COVID-19 vaccinees. Demographic, clinical data and repeated blood samples&#xD;
      will be collected to evaluate the complications and kinetics, duration and breadth of the&#xD;
      immune responses comparing natural infection to vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study is&#xD;
&#xD;
        -  To compare immune responses after natural SARS-CoV-2 infection and COVID-19 vaccination&#xD;
           The secondary aims are&#xD;
&#xD;
        -  To compare the duration and breadth of antibody responses between natural infection and&#xD;
           vaccination.&#xD;
&#xD;
        -  To investigate the duration and breadth of B and T cellular responses between natural&#xD;
           infection and vaccination.&#xD;
&#xD;
        -  To evaluate the short and long term complications after natural infection and&#xD;
           vaccination.&#xD;
&#xD;
        -  To find out if previous infection skews the immune response after vaccination.&#xD;
&#xD;
        -  To study reinfection after natural infection and vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Anticipated">January 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>immune responses</measure>
    <time_frame>2 months to 3 years</time_frame>
    <description>spike antibody response to SARS-CoV-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration and breadth of B- and T cell responses</measure>
    <time_frame>2 months to 3 years</time_frame>
    <description>compare vaccination to natural infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune responses in healthy people and patient groups at risk</measure>
    <time_frame>2 months to 3 years</time_frame>
    <description>compare between vaccination groups</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Health care workers</arm_group_label>
    <description>500-1000 health care workers prioritized for early vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prioritized patient populations</arm_group_label>
    <description>2000 individuals in patient populations prioritized for vaccinations</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>covid-19 vaccine</intervention_name>
    <description>vaccination</description>
    <arm_group_label>Health care workers</arm_group_label>
    <arm_group_label>prioritized patient populations</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood collection including cells.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Comparator group: patients with natural SARS-CoV-2 infection Vaccine groups: Health care&#xD;
        workers and high-risk population groups.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects prioritized by national vaccination program&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children&#xD;
&#xD;
          -  unable or unwilling to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Rebecca J Cox, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bergen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca J Cox, PhD</last_name>
    <phone>+4745242974</phone>
    <email>rebecca.cox@uib.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Langeland, MD</last_name>
    <phone>+4741616450</phone>
    <email>nina.langeland@uib.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Bergen</name>
      <address>
        <city>Bergen</city>
        <zip>5020</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca J Cox, PhD</last_name>
      <phone>45242974</phone>
      <email>rebecca.cox@uib.no</email>
    </contact>
    <contact_backup>
      <last_name>Nina Langeland, MD</last_name>
      <phone>41616450</phone>
      <email>nina.langeland@uib.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Cox RJ, Brokstad KA, Krammer F, Langeland N; Bergen COVID-19 Research Group. Seroconversion in household members of COVID-19 outpatients. Lancet Infect Dis. 2021 Feb;21(2):168. doi: 10.1016/S1473-3099(20)30466-7. Epub 2020 Jun 15. Erratum in: Lancet Infect Dis. 2020 Sep;20(9):e215.</citation>
    <PMID>32553187</PMID>
  </reference>
  <reference>
    <citation>Trieu MC, Bansal A, Madsen A, Zhou F, Sævik M, Vahokoski J, Brokstad KA, Krammer F, Tøndel C, Mohn KGI, Blomberg B, Langeland N, Cox RJ. SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. J Infect Dis. 2020 Nov 28. pii: jiaa737. doi: 10.1093/infdis/jiaa737. [Epub ahead of print]</citation>
    <PMID>33247924</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bergen</investigator_affiliation>
    <investigator_full_name>Rebecca Cox</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Vaccine</keyword>
  <keyword>SARS-CoV-2 antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be developed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

